• Mashup Score: 0

    Background The risk of extracolonic cancer is increased in inflammatory bowel disease (IBD) patients, but it is not clear whether there is a causal relationship. We aimed to systematically estimate the causal relationship between IBD and extracolonic cancers. Methods Independent genetic variants strongly associated with IBD were extracted as instrumental variables from genome-wide association study (GWAS) conducted by the International IBD Genetics Consortium including 12,882 IBD patients, 5956 Crohn’s disease (CD) patients, and 6968 ulcerative colitis (UC) patients. Three sources of cancer GWAS were selected as outcome data. Two-sample Mendelian randomization (MR) analysis was conducted to assess the causal effects of IBD on 32 extracolonic cancers. The meta-analysis was applied to assess the combined causal effect with multiple MR results. Results IBD, CD, and UC have potential causal associations with oral cavity cancer (IBD: OR = 1.180, 95% CI: 1.059 to 1.316, P = 0.003; CD: OR = 1

    Tweet Tweets with this article
    • Genetically predicted #InflammatoryBowelDisease suggested to be a risk factor in the development of oral cavity and breast #cancer via #MendelianRandomization Hui Gao et al. publish in #BMCMedicine https://t.co/LseT9HpdTV https://t.co/5Q5rcrhChy

  • Mashup Score: 7

    Objectives Interleukin (IL) 17s cytokines are key drivers of inflammation that are functionally dysregulated in several human immune-mediated inflammatory diseases (IMIDs), such as rheumatoid arthritis (RA), psoriasis and inflammatory bowel disease (IBD). Targeting these cytokines has some therapeutic benefits, but issues associated with low therapeutic efficacy and immunogenicity for subgroups of patients or IMIDs reduce their clinical use. Therefore, there is an urgent need to improve the coverage and efficacy of antibodies targeting IL-17A and/or IL-17F and IL-17A/F heterodimer. Methods and results Here, we initially identified a bioactive 20 amino acid IL-17A/F-derived peptide (nIL-17) that mimics the pro-inflammatory actions of the full-length proteins. Subsequently, we generated a novel anti-IL-17 neutralising monoclonal antibody (Ab-IPL-IL-17) capable of effectively reversing the pro-inflammatory, pro-migratory actions of both nIL-17 and IL-17A/F. Importantly, we demonstrated th

    Tweet Tweets with this article
    • Novel biologic Ab-IPL-IL-17 shows promise for #rheumatoidarthritis and #inflammatoryboweldisease https://t.co/7iU0sWA6F8 https://t.co/SZs3isaFm5

  • Mashup Score: 1

    Objective The diagnosis of axial spondyloarthritis (axSpA) is hampered by diagnostic delay. Computed tomography (CT) undertaken for nonmusculoskeletal (non-MSK) indications in patients with inflammatory bowel disease (IBD) offers an opportunity to identify sacroiliitis for prompt rheumatology referral. This study aims to identify what proportion of patients with IBD who underwent abdominopelvic…

    Tweet Tweets with this article
    • Research Article Identifying Axial Spondyloarthritis in Patients With Inflammatory Bowel Disease Using Computed Tomography 📰 https://t.co/fL7bj7MMWs #spondyloarthritis #inflammatoryboweldisease #screeningtool #imaging https://t.co/gW5sjzVy9S

  • Mashup Score: 0

    In individuals with inflammatory bowel disease (IBD), extraintestinal manifestations (EIMs) represent a significant burden of illness, with reported prevalence rates of up to 50%.1 Of the various types of EIMs, the most commonly involved organ system is the musculoskeletal system. The 2 major clinical phenotypes are axial spondyloarthritis (axSpA) and peripheral SpA, which have been reported in…

    Tweet Tweets with this article
    • Editorial A Joint Effort: Improving the Identification of Spondyloarthritis in Patients With Inflammatory Bowel Disease 📰 https://t.co/bnRXDXLsVu #spondyloarthritis #inflammatoryboweldisease https://t.co/5wLk72r35l